More than 55 Roswell Park Cancer Institute (RPCI) employees and supporters went Bald for Bucks today to raise funds for the fight against cancer, and to show their support for patients and their families.

Seven Roswell Park Cancer Institute (RPCI) teams have been invited to present their research at the 69th annual Cancer Symposium of the Society of Surgical Oncology (SSO), March 2–5 in Boston, Mass. Roswell Park faculty and fellows will present on several topics, including two novel calculators that help predict overall survival rates for patients diagnosed with esophageal and liver cancers.

In a demonstration of unprecedented regional commitment to fighting colorectal cancer, Roswell Park Cancer Institute today joined other local health care systems and health insurers in pledging support for the American Cancer Society’s 80% by 2018 initiative, an effort to make sure that 80% of adults age 50 and older are getting recommended screening for colorectal cancer by 2018.

A team of Roswell Park Cancer Institute researchers has developed and evaluated the first intravital microscopy system shown to be safe for use in humans. Writing in the journal Nature Communications, the scientists report that their proprietary technology enabled them, for the first time ever, to visualize tumor blood vessels in real time.

For nearly a decade, Roswell Park Comprehensive Cancer Center has collaborated with Cleveland BioLabs Inc. (CBLI), a Buffalo-based company, to support the development of a drug that has applications as both a cancer immunotherapy and a radiation countermeasure. They recently published the latest findings from these combined efforts in the journal Proceedings of the National Academy of Sciences of the United States of America.

A combination therapeutic approach to aggressive B-cell lymphoma cell lines resulted in cancer cell death, according to scientists in the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute (RPCI). The study was published in a recent issue of Oncoscience.

Investigators at Roswell Park Comprehensive Cancer Center have garnered nearly $7 million in recent research grants. The awards include a five-year, $2.4 million grant from the National Cancer Institute (NCI) to optimize a particular approach for administering photodynamic therapy (PDT), a form of cancer therapy that was developed at Roswell Park in the 1970s.